Product Images Levetiracetam

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 17 images provide visual information about the product associated with Levetiracetam NDC 70518-3803 by Remedyrepack Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Remedy_Label - Remedy Label

Remedy_Label - Remedy Label

This is a description of a medication called LevETIRAcetam in oral solution form. Each cup contains 750mg of the medication in 7.5 mL. The package includes 10 cups of this solution. The medication is repackaged by RemedyRepack Inc. The prescription is only available with a prescription. The NDC number for the medication is 70518-3802-00. The expiration date and lot number are not mentioned in the provided text. The medication is manufactured by Aurohindo in Nagar, India. It is important to store the medication at a temperature between 20-25°C (88-77°F) and excursions are permitted between 15-30°C (59-86°F) as per the USP guidelines. It is important to keep this medication and all medications out of the reach of children. The provided text does not include specific usage instructions, so it is recommended to refer to the package insert for more information.*

MM5 - levETIRAcetam 1250mg 12.5mL 70518 3803 04

MM5 - levETIRAcetam 1250mg   12.5mL 70518 3803 04

MM6 - levETIRAcetam 1250mg 12.5mL 70518 3803 05

MM6 - levETIRAcetam 1250mg   12.5mL 70518 3803 05

MM9 - levETIRAcetam 1500mg 15mL 70518 3803 08

MM9 - levETIRAcetam 1500mg   15mL 70518 3803 08

This is a description of a medication called levETIRAcetam. It is an oral solution with a strength of 1500mg / 15mL. The package contains 10 cups, each with 15mL of the solution. The medication is manufactured by Aurohindo in Nagar, India. The NDC number is 70518-3802-08 and the source NDC is 65862-0250-47. The medication should be stored at 20-25°C (88-77°F), with excursions permitted between 15-30°C (59-86°F). The medication is repackaged by RemedyRepack Inc. in Indiana, PA. The lot number and expiration date are not available. It is important to keep this medication and all medications out of the reach of children. For further instructions, please refer to the package insert.*

MM10 - levETIRAcetam 1500mg 15mL 70518 3803 09

MM10 - levETIRAcetam 1500mg   15mL 70518 3803 09

MM7 - levETIRAcetam 2000mg 20mL 70518 3803 06

MM7 - levETIRAcetam 2000mg   20mL 70518 3803 06

This is a description of a medication called levETIRAcetam. It is an oral solution with a strength of 2000mg / 20 mL. The medication is packaged in cups, with each cup containing 20mL of the solution. The medication is repackaged by RemedyRepack Inc. and the original manufacturer is Aurohindo located in Nagar, India. The medication should be stored at a temperature between 20-25°C (88-77°F), with excursions permitted between 15-30°C (59-86°F). It is important to keep this medication out of the reach of children.*

MM8 - levETIRAcetam 2000mg 20mL 70518 3803 07

MM8 - levETIRAcetam 2000mg   20mL 70518 3803 07

This is a description of a medication labeled as "levETIRAcetam." It is an oral solution with a strength of 2000mg per 20 mL. The product is packaged in a 20 mL container and must be stored at a temperature range of 20-25°C (88-77°F) with excursions permitted up to 15-30°C (59-86°F). The medication is intended for use as directed, and caution must be taken to keep it out of the reach of children. The manufacturing company is Aurohindo, located in Nagar, India. The product has been repackaged by RemedyRepack Inc. in Indiana, PA.*

MM3 - levETIRAcetam 500mg 5mL 70518 3803 02

MM3 - levETIRAcetam 500mg   5mL 70518 3803 02

This is an evaluation of a medication labeled as "levETIRAcetam." It is an oral solution with a strength of 500mg/5mL. The package contains 10 cups, each with a volume of 5mL. The medication should be stored at temperatures between 20-25°C (88-77°F) with excursions permitted between 15-30°C (59-86°F) according to USP guidelines. The manufacturer is Aurohindo located in Nagar, India. The medication is repackaged by RemedyRepack Inc. in Indiana, PA. The NDC code for this medication is 70518-3802-02, and the source NDC is 65862-0250-47. The lot number and expiration date are not provided. It is important to keep this medication out of the reach of children.*

MM4 - levETIRAcetam 500mg 5mL 70518 3803 03

MM4 - levETIRAcetam 500mg   5mL 70518 3803 03

This text provides information about a medication labeled as "R A RX ONLY". The medication is an Oral Solution with a concentration of 500mg in 5 mL. The NDC (National Drug Code) for this medication is 70518-3802-02. The manufacturing company is Aurohindo located in Nagar, India. The expiration date and lot number are not available in the provided text. The source NDC for the medication is 65862-0250-47. The text also mentions to keep this medication, along with all others, out of the reach of children. The medication is packed by RemedyRepack Inc., located in Indiana, PA (Pennsylvania) with contact number 724.465.8762. The directions for use are indicated on the package insert. The recommended storage temperature is between 20-25°C (68-77°F), with excursions permitted between 15-30°C (59-86°F) according to USP (United States Pharmacopeia) guidelines.*

MM2 - levETIRAcetam 750mg 7.5mL 70518 3803 01

MM2 - levETIRAcetam 750mg   7.5mL 70518 3803 01

This is a description of a medication. The medication is called levETIRAcetam and it is in the form of an oral solution with a strength of 750mg / 7.5 mL. The package contains 7.5 mL of the medication. The medication is intended for use as directed, which can be found in the package insert. It should be stored between 20-25°C (88-77°F), with excursions permitted between 15-30°C (59-86°F). The medication was repackaged by RemedyRepack Inc. in Indiana, PA. The manufacturer of the medication is Aurohindo, located in Nagar, India. The product is for prescription use only and should be kept out of the reach of children. The expiration date and lot number are not available in the provided text.*

Figure 1: Responder Rate (≥50% Reduction from Baseline) in Study 1 - levetiracetam fig1

Figure 1: Responder Rate (≥50% Reduction from Baseline) in Study 1 - levetiracetam fig1

Figure 1 shows the responder rate in Study 1, indicating a reduction of 250% from the baseline. The text also mentions Lovcasetam and Lovtiactan, with their respective doses of 100 mg and 3000 mg. The results are statistically significant compared to the placebo.*

Figure 2: Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A - levetiracetam fig2

Figure 2: Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A - levetiracetam fig2

Figure 3: Responder Rate (≥50% Reduction from Baseline) in Study 3 - levetiracetam fig3

Figure 3: Responder Rate (≥50% Reduction from Baseline) in Study 3 - levetiracetam fig3

Figure 4: Responder Rate (≥ 50% Reduction from Baseline) in Study 4 - levetiracetam fig4

Figure 4: Responder Rate (≥ 50% Reduction from Baseline) in Study 4 - levetiracetam fig4

Figure 5: Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5 - levetiracetam fig5

Figure 5: Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5 - levetiracetam fig5

The text provides data on the "Responder Rate" for patients aged between 1 month to less than 4 years in Study 5. The percentages indicate the reduction from baseline for different groups. Unfortunately, the exact details of the reduction are not available due to incomplete . However, it is mentioned that there is a statistically significant difference between the placebo group (N=51) and the levetiracetam group (N=58).*

Table 15: Median Percent Reduction from Baseline in PGTC Seizure Frequency per Week in Study 7 - levetiracetam fig6

Table 15: Median Percent Reduction from Baseline in PGTC Seizure Frequency per Week in Study 7 - levetiracetam fig6

This text provides information about a study (Study 7) evaluating the responder rate (250% reduction from baseline) in the frequency of generalized tonic-clonic (PGTC) seizures per week. The figure shows the percentage of patients who experienced a reduction in PGTC seizure frequency. The percentage of responders is shown on the y-axis, ranging from 0% to 100%, while the x-axis represents the treatment groups (Placebo and Levetiracetam). The text indicates that the results for Levetiracetam were statistically significant compared to the placebo group.*

Chemical Structure - levetiracetam str

Chemical Structure - levetiracetam str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.